Compare FTAI Aviation Ltd (FTAI) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Travere Therapeutics Inc. Common Stock — how do they compare? FTAI Aviation Ltd trades at $162 (market cap $17.14B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: FTAI Aviation Ltd is far larger — about 3.5× Travere Therapeutics Inc. Common Stock's market cap, and FTAI Aviation Ltd pays a 1.2% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 24 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FTAI | TVTX | |
|---|---|---|
Market Cap | $17.14B | $4.88B |
Volume | 3,282,791 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $310.04 | $67.52 |
52-Week Low | $152.80 | $26.79 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $20.25B | $5.01B |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $166.87, up 0.81% today, but technical indicators signal a bearish trend with key support at $163 and resistance at $169. The company reported strong 2025 revenue of $2.51 billion and net income of $501 million, though recent quarters have missed EPS expectations. Recent developments include a $500 million share buyback program and a strategic acquisition of 27 Boeing 737-700 aircraft, highlighting growth initiatives in aerospace services.
The outlook is mixed: analyst consensus is unanimously bullish with a $321.25 price target, but risks include volatile cash flows and competitive pressures. Upside potential hinges on execution of the buyback and aerospace segment growth, while earnings misses and negative operating cash flow pose near-term challenges for investors.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
